MENU

06.11.20

Dihydroergotamine Delivered to Upper Nasal Cavity is Safe and Effective for Acute Migraine Treatment

  • KEYWORDS:
  • Dihydroergotamine
  • dihydroergotamine mesylate
  • Headache
  • Migraine

Dihydroergotamine delivered to the upper nasal cavity (DHE-POD) (INP104; Impel NeuroPharma, Seattle, WA) effectively and safely relieved migraine pain in the STOP-301 phase 3 clinical trial (NCT03557333) study relieved migraines safely and effectively, with no new safety signals or concerning trends in nasal safety findings. Although DHE has a high response rate and sustained efficacy, use has been limited by its accessibility only as an invasive injectable or in other forms with high dosing variability. 

In the STOP-301 study, 66.3% of participants attained pain relief and 38% of participants attained pain freedom at 2 hours following their first dose of DHE-POD. In the primary safety set (PSS) (n=185), 33.1% of participants who took an average of 2 or more DHE-POD treatments per 28-day period over 24 weeks attained pain freedom at 2 hours. Initial onset of pain relief began as early as 15 minutes for 16.3% of participants, which continued to improve over time. Additionally, sustained pain freedom was observed in the majority of participants, with 98.4% and 95% of participants reporting no recurrence of their migraine or use of rescue medications during the 24- and 48-hour periods after using DHE-POD during weeks 21 to 24. 

Over 5,650 migraine attacks were treated during this evaluation of self-administered intermittent use of DHE-POD for up to 52 weeks and collected in a diary to explore efficacy of DHE-POD as assessed by participant-reported change from baseline migraine measures.

In the study, DHE-POD delivered 1.45 mg, less than 72.5% of the currently approved dose (2 mg). Optimal dosing is critical so participants may stand to benefit from the established efficacy profile of DHE-POD, without the potentially triggering undesired side effects that can be experienced with delivering higher doses of drug to the lower nasal space. The most frequently reported adverse events (≥5%) during the entire 24-week period were nasal congestion (15%), nausea (6.8%), nasal discomfort (5.1%), and unpleasant taste (5.1%). 

Further analysis of the STOP-301 study will be ongoing and will be submitted for future publication. A new drug application (NDA) for DHE-POD will be submitted to the Food & Drug Administration (FDA) in the second half of 2020.
 

FDA Approves Inebilizumab for the Treatment of Neuromyelitis Optica Spectrum Disorder

Previous News Article

Children Treated With Nusinersen Continue Meeting Developmental Motor Milestones

Next News Article
This Month's Issue
Epilepsy and Autism

Alyssa R. Rosen, MD

Epilepsy and Cognition

Barbara C. Jobst, MD